This post was originally published on this site
The company’s previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion.
AbbVie (NYSE:ABBV) also expects peak sales of the drugs to exceed $21 billion in 2027. The two drugs are part of the company’s long-term growth strategy to offset Humira’s loss of exclusivity.
The drugmaker has been in contract negotiations with insurers and pharmacy benefit managers for Humira for this year, and said in October that pricing of its rivals would determine the drug’s sales this year.
